Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 29 | ICEECE2012 | Next issue

15th International & 14th European Congress of Endocrinology

Oral Communications

Pituitary Clinical 2

ea0029oc10.1 | Pituitary Clinical 2 | ICEECE2012

Predictors of morbidity and mortality in acromegaly: an Italian survey on behalf of the Italian study group of acromegaly

Arosio M. , Reimondo G. , Berchialla P. , Malchiodi E. , Montefusco L. , Terzolo M.

This study presents epidemiological data of 1512 Italian acromegalic patients who had been diagnosed from 1980 to 2002 and followed-up for more than 10 years, retrospectively collected by 24 tertiary referral centers. Data on co-morbidities and mortality were compared to those of the general Italian population obtained by the Italian National Institute of Statistic. At diagnosis median age of patients (41% M, 59% F) was 46 years, GH (mean±S.D.) 31±37 m...

ea0029oc10.2 | Pituitary Clinical 2 | ICEECE2012

Food intake regulating hormones in adult craniopharyngioma patients

Roemmler J. , Geigenberger V. , Otto B. , Bidlingmaier M. , Dimopoulou C. , Stalla G. , Schopohl J.

Introduction: Patients with craniopharyngeoma often have disturbances of the hypothalamic–pituitary axis and serious comorbidities as obesity. We hypothesized, that the pattern of hormones regulating the nutritional status is worsened in adult patients with craniopharyngioma (CP) compared to adult patients with non-functioning pituitary adenoma (NFPA).Methods: We included 33 patients with CP (m=16, f=17, median age: 48 years (26–7...

ea0029oc10.3 | Pituitary Clinical 2 | ICEECE2012

Pathophysiology of renal calcium handling in acromegaly revisited

Kamenicky P. , Blanchard A. , Gauci C. , Salenave S. , Letierce A. , Lombes M. , Azizi M. , Prie D. , Souberbielle J. , Chanson P.

Background: Hypercalciuria is frequent in patients with acromegaly, but it is unclear how GH/insulin-like growth factor 1 (IGF1) regulate renal calcium handling. Elevated fasting plasma calcium levels despite increased glomerular filtration suggest enhanced renal calcium reabsorption.Objective: To investigate the impact of acromegaly on phosphocalcium metabolism.Design: Prospective sequential study (ClinicalTrials.gov Identifier: N...

ea0029oc10.4 | Pituitary Clinical 2 | ICEECE2012

Higher glucocorticoid supplementation doses are associated with increased overall mortality in patients with non-functioning pituitary adenoma

Zueger T. , Kirchner P. , Herren C. , Allemann S. , Fischli S. , Zwahlen M. , Christ E. , Stettler C.

Introduction: Current treatment guidelines for patients with insufficiency of the hypothalamic pituitary adrenal (HPA) axis recommend weight adjusted glucocorticoid supplementation doses to minimize risk of negative side effects (e.g. osteoporosis etc).However, little is known on a potential dose-dependent effect of glucocorticoid supplementation on overall mortality in patients with pituitary disease. Non-functioning pituitary adenoma (NFPA) is one of t...

ea0029oc10.5 | Pituitary Clinical 2 | ICEECE2012

Once-weekly, CTP-modified hGH (MOD-4023) is effective in growth hormone deficient adults: a phase II, dose and frequency finding study

Popovic V. , Goth M. , Vanuga P. , Payer J. , Pfeifer M. , Bidlingmaier M. , Fima E.

Objective: GH replacement therapy currently requires daily injections, which may cause poor compliance and distress for patients. CTP-modified hGH (MOD-4023) is being developed for once-weekly administration in GH Deficient adults and children. The present study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of MOD-4023 in GHD adults.Design and methods: 39 normalized GHDA patients currently treated with daily GH were randomized and...

ea0029oc10.6 | Pituitary Clinical 2 | ICEECE2012

Second neoplasms in childhood cancer survivors with growth hormone deficiency treated or not treated with GH

Felicetti F. , Di Cuonzo D. , Manicone R. , Lazzarato F. , Biasin E. , Chiabotto P. , Boccuzzi G. , Brignardello E.

Introduction: The relation between GH treatment and cancer is still matter of debate. Childhood cancer survivors (CCS) have a high risk to develop second benign and malignant neoplasms (SNs), mainly as a consequence of radiation therapy. Thus, in patients with GH deficiency it is difficult to discriminate the oncological risk due to GH treatment from that caused by anticancer therapy and by individual susceptibility.Methods: We studied the prevalence of ...